Jubilant Draximage Inc.
http://www.draximage.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jubilant Draximage Inc.
Med Discovery SA
Switzerland's Med Discovery was founded on the discovery of a prostate cancer target, human kallikrein 2, a key protease associated with prostate biology that is thought to contribute to cancer progression and development. The start-up's lead protease inhibitor targets hK2 and is based on the natural serine protease inhibitor ACT, which the company believes will avoid the selectivity and toxicities of other protease inhibitors. Med Discovery is developing the candidate for prostate cancer, but it believes it also has potential for treating skin disorders and for immunological treatment of cancer.
Molecular Targeting Technology Inc.
Molecular Targeting Technology is developing radiopharmaceuticals for nuclear medicine and targeting agents for drug delivery. The company's lead product, {Amiscan} uses a small-molecule radiotracer to diagnose heart attack.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice